Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial

Fig. 3

Decrease in 25(OH)D2 and 25(OH)D3 levels from randomization to day-28 (a and c) or day-56 (b and d). Bars represent means and standard errors. a and b, study-1: participants were randomized to a single oral dose of 50,000 IU D2 (solid bars) or placebo (open bars). c and d, study-2: participants were randomized to a single oral dose of 50,000 IU D3 (solid bars) or placebo (open bars) four days after receiving a single oral dose of 50,000 IU D2. 25(OH)D2, 25-hydroxyvitamin D2. 25(OH)D3, 25-hydroxyvitamin D3. *, p < 0.001

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us